Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zhaoke Ophthalmology Limited
兆科眼科有限公司
(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)
(Stock Code: 6622)

VOLUNTARY ANNOUNCEMENT – ENTERING INTO DISTRIBUTION AGREEMENT WITH PT FERRON TO COMMERCIALIZE BRIMOCHOL™ PF IN INDONESIA

This announcement is made by the board of directors (the "**Board**") of Zhaoke Ophthalmology Limited (the "**Company**") on a voluntary basis.

The Board of the Company is pleased to announce that the Company has entered into a distribution and supply agreement with the leading Indonesian pharmaceutical company PT Ferron Par Pharmaceuticals ("**PT Ferron**"), for the domestic commercialization of BRIMOCHOL™ PF, an innovative drug for the treatment of presbyopia, licensed from Tenpoint Therapeutics, Ltd. ("**Tenpoint**") (the "**Product**"), in Indonesia.

Under the terms of the agreement, the Company grants PT Ferron exclusive rights to import, promote, distribute, market, and sell the Product in Indonesia. The Company will receive an upfront payment and is eligible to receive additional milestone payments based on specific achievements.

In June 2025, Tenpoint, developer of BRIMOCHOL™ PF, announced that the U.S. FDA had accepted the New Drug Application ("**NDA**") for the drug. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026, for BRIMOCHOL™ PF.

ABOUT BRIMOCHOL™ PF AND BRIO-II PHASE 3 STUDY

BRIMOCHOL™ PF is an investigational, preservative-free, once daily eyedrop to correct for the loss of near vision associated with aging. BRIO-II is a 3-arm, multicenter, randomized, double-masked, safety and efficacy study of BRIMOCHOL™ PF (carbachol/brimonidine tartrate fixed-dose combination) topical ophthalmic solution vs. carbachol monotherapy topical ophthalmic solution vs. a vehicle topical ophthalmic solution in subjects with emmetropic phakic or pseudophakic presbyopia (NCT05135286). The study enrolled 629 subjects across forty-seven sites in the United States.

ABOUT PRESBYOPIA

Presbyopia is the gradual loss of near vision associated with aging, making it difficult to perform tasks like reading fine print. It typically begins in adults in their 40s [1] and becomes almost universal by age 50 [2]. Presbyopia impacts billions of people globally [3] with approximately 600 million adults affected in China, South Korea and Southeast Asia [4]. In Australia, the total number of prevalence cases reached over 13.5 million in 2023, according to GlobalData [5]. Reading glasses are the most common solution for near-vision correction; however, many people find glasses inconvenient or prefer not to wear them for aesthetic reasons. There are currently no approved presbyopia-correcting therapeutics in many countries across the Asia-Pacific region.

ABOUT PT FERRON PAR PHARMACEUTICALS

PT Ferron Par Pharmaceuticals, a member of Dexa Group, is a fast-growing pharmaceutical company that started its operation in 2001. PT Ferron has become top 15 largest pharmaceutical operations in Indonesia (IQVIA, IPA+IHPA MAT Q1 2025). Its facility has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA, the United Kingdom), and the National Authority of Medicines and Health Products (Infarmed, Portugal). With a diverse product portfolio, advanced manufacturing capabilities, and strong strategic partnerships, PT Ferron continues to strengthen its market presence and operational excellence.

1 World report on vision. (2019). Retrieved 29 April, 2022, from https://www.who.int/docs/default-source/documents/world-vision-report-post-launch-accessible.pdf?sfvrsn=1b29f0e7_2

2 Polat, U., Schor, C., Tong, JL. et al. Training the brain to overcome the effect of aging on the human eye. Sci Rep 2, 278 (2012). https://doi.org/10.1038/srep00278

3 Market Scope, Global Presbyopia-Correcting Surgery Market Report. April 2012.

4 Tenpoint Therapeutics data on file.

5 GlobalData's Epidemiology Market Size Search extracted on 18 December 2024.

ABOUT TENPOINT THERAPEUTICS

Tenpoint Therapeutics Ltd. is a global, commercial-ready biotechnology company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its lead asset, BRIMOCHOL™ PF, is a novel pupil-modulating, investigational therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately two billion people globally. Tenpoint Therapeutics has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for BRIMOCHOL™ PF, has filed the New Drug Application (NDA) and has received a Prescription Drug User Fee Act (PDUFA) date from the U.S. Food and Drug Administration (FDA) of January 28, 2026. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, November 6, 2025

As at the date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.